Table 2.

Univariate and multivariate analyses of survival

	n	Univariate			Multivariate
		OS, months	95% CI	p value	HR	95% CI	p value
Gender
Male	630	9.0	8.1–9.8	0.292	-	-	-
Female	155	9.2	7.2–11.2
Aetiology
Non-viral	323	8.7	7.8–9.6	0.006	-	-	0.103
Hepatitis B virus	183	6.8	5.4–8.2		1.04	0.83–1.29
Hepatitis C virus	279	11.3	9.4–13.2		0.84	0.69–1.01
Geography				0.074	-	-	-
Western	479	9.1	8.2–10.0
Eastern	306	8.5	7.1–9.9
α-Fetoprotein
>400 ng/mL	459	11.8	10.2–13.3	<0.001	-	-	<0.001
<400 ng/mL	302	5.6	4.7–6.6		1.82	1.53–2.16
Portal vein invasion
Absent	567	9.9	8.8–11.1	<0.001	-	-	-
Present	218	5.9	4.7–7.0
Extrahepatic spread
Absent	479	9.7	8.6–10.8	<0.001	-	-	-
Present	293	7.0	5.7–8.3
Child-Pugh class
A	400	9.2	7.9–10.5	0.016	-	-	0.046
B	342	8.6	7.6–9.6		1.19	1.00–1.41
BCLC stage
A/B	289	12.7	10.3–15.2	<0.001	-	-	<0.001
C	496	7.0	6.1–7.9		1.65	1.38–1.98
Treatment group
Pre-treated	521	10.5	9.2–11.8	<0.001	-	-	0.002
Treatment naïve	264	6.6	5.6–7.6		1.32	1.10–1.57

Bold type denotes significance. OS, overall survival; BCLC, Barcelona Clinic Liver Cancer.